Cargando…

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

OBJECTIVES: We examined the long-term effects of everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. METHODS: Following favorable results from the double-blind core phase of EXIST-2 (NCT00790400), patients were allowed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bissler, John J., Kingswood, J. Chris, Radzikowska, Elzbieta, Zonnenberg, Bernard A., Belousova, Elena, Frost, Michael D., Sauter, Matthias, Brakemeier, Susanne, de Vries, Petrus J., Berkowitz, Noah, Voi, Maurizio, Peyrard, Severine, Budde, Klemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549893/ https://www.ncbi.nlm.nih.gov/pubmed/28792952 http://dx.doi.org/10.1371/journal.pone.0180939

Ejemplares similares

Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2
por: Bissler, John J, et al.
Publicado: (2019)

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
por: Bissler, John J., et al.
Publicado: (2018)

The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma
por: Bissler, John J., et al.
Publicado: (2017)

Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex
por: Sparagana, Steven, et al.
Publicado: (2017)

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
por: Franz, David N., et al.
Publicado: (2016)

TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
por: Kingswood, J. Chris, et al.
Publicado: (2021)

Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide
por: Davies, Mark, et al.
Publicado: (2017)

Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disorders
por: Krueger, Darcy A., et al.
Publicado: (2017)

Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis
por: Franz, David N., et al.
Publicado: (2015)

Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness
por: Kingswood, J Chris, et al.
Publicado: (2019)

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures
por: Franz, David N., et al.
Publicado: (2018)

Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA)
por: Sauter, Matthias, et al.
Publicado: (2021)

Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study
por: Nabbout, Rima, et al.
Publicado: (2018)

Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex
por: Jansen, Anna C., et al.
Publicado: (2019)

Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus
por: Zonnenberg, Bernard A., et al.
Publicado: (2018)

Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study
por: Jansen, Anna C., et al.
Publicado: (2020)

Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC)
por: Brakemeier, Susanne, et al.
Publicado: (2017)

Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry
por: Nabbout, Rima, et al.
Publicado: (2021)

TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex
por: Kingswood, John C, et al.
Publicado: (2014)

TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients
por: Kingswood, John C., et al.
Publicado: (2017)

Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry
por: Marques, Ruben, et al.
Publicado: (2019)

The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases
por: Marques, Ruben, et al.
Publicado: (2019)

Real-World Evidence Study on the Long-Term Safety of Everolimus in Patients With Tuberous Sclerosis Complex: Final Analysis Results
por: Ruiz-Falcó Rojas, María Luz, et al.
Publicado: (2022)

Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project
por: de Vries, Petrus J., et al.
Publicado: (2020)

Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex
por: Brakemeier, Susanne, et al.
Publicado: (2018)

Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study
por: Jansen, Anna C., et al.
Publicado: (2019)

Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas
por: Kingswood, J. Chris, et al.
Publicado: (2020)

Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype
por: de Vries, Petrus J., et al.
Publicado: (2020)

The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial
por: Randell, Elizabeth, et al.
Publicado: (2016)

Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial
por: Franz, David N., et al.
Publicado: (2018)

Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR)
por: Brakemeier, Susanne, et al.
Publicado: (2019)

A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report
por: Auvin, Stéphane, et al.
Publicado: (2019)

Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
por: Park, Sung-Min, et al.
Publicado: (2018)

Everolimus induced organizing pneumonia in a patient with tuberous sclerosis complex
por: Lanfranco, Julio, et al.
Publicado: (2021)

Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex
por: Daccord, Cécile, et al.
Publicado: (2020)

Individualized everolimus treatment for tuberous sclerosis-related angiomyolipoma promotes treatment adherence and response
por: Chung, Noelle K X, et al.
Publicado: (2022)

Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior()()()
por: Gipson, Tanjala T., et al.
Publicado: (2013)

Erratum: Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus
por: Park, Sung-Min, et al.
Publicado: (2018)

Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis
por: Shibata, Yuka, et al.
Publicado: (2019)

Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
por: Overwater, Iris E, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_emvdvtd8ted7vies9qps88vqrs